BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ADBRY (tralokinumab-ldrm) by Leo Pharma is interleukin-13 antagonists [moa]. First approved in 2021.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADBRY (tralokinumab-ldrm) is a monoclonal antibody that selectively blocks interleukin-13, a key driver of type 2 inflammation. It is approved for moderate-to-severe atopic dermatitis in adults. The drug targets the IL-13 pathway to reduce skin inflammation and pruritus in patients with inadequate response to topical therapies.
$32MPart D
PeakProduct is in peak commercial phase with modest Part D penetration (~$32M), indicating stable but not dominant market position within the IL-13 antagonist class for atopic dermatitis.
Mechanism of Action
Interleukin-13 Antagonists
Pharmacologic Class:
Interleukin-13 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ADBRY is a mature, commercially-launched biologic in a competitive dermatology market with stable but modest uptake. Career positions will center on defending market share, managing payer relationships, and educating dermatologists in a crowded IL-13/IL-4Rα space rather than growth-phase expansion.
Brand ManagerMedical Science Liaison
Worked on ADBRY at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.